Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Luhmann who wrote (8305)	3/1/1998 7:53:00 PM
From: Caroline and Daughters	Read Replies (1) \| Respond to of 14328

Ok Ok Ok is it time we start preparing the mint julips? El Scripto get your shovel ready to dig up Rhett Butler he has to serve them to me you know. I think I will start some sort of a contest as to what it will take to get this stock to move up into the teens. Start posting your ideas immediatley if not sooner. Grunt

To: Ron Luhmann who wrote (8305)	3/1/1998 8:09:00 PM
From: Keiko	Respond to of 14328

ADVANCES IN HIV TESTING ---RAPID TESTING * During the 9 years since the last recommendation for reporting HIV test results was issued, HIV testing technology has evolved substantially. The benefit of knowing one's sero-status has markedly increased due to effective therapeutics for HIV - infected persons and effective strategies for prevention among uninfected persons. CDC and PHS have been discussing for some time the current state of testing and related health issues in light of the technologic advances in rapid screening tests, and the increased health benefits that may be afforded by more quickly initiating new, effective therapies for HIV. The debate recently over the use of rapid tests is being fueled by data indicating that follow-up HIV tests is often poor. In some public settings, many clients fail to return for test results and post test counseling. Since rapid tests allow the provision of results and result - specific counseling on the day of the initial visit, such tests could potentially increase the efficiency of HIV counseling and testing. While many of the rapid tests commonly used around the world have been developed by US manufacturers, but few, if any, of these manufacturers are currently pursuing FDA approval. Since the current recommendations preclude providing results from positive screening tests ( including rapid tests ) the market for rapid tests in the US may be too small to justify the cost and time necessary to receive FDA approval. A modification to the PHS recommendation might encourage more US manufacturers to seek FDA approval. The current PHS algorithm precludes reporting the results to individuals from positive screening results, including those from rapid tests. Under the PHS recommendation , no positive test results can be given to clients/ patients until a screening test has been repeatedly reactive on the same specimen and a supplemental, more specific test such as the Western Blot has been used to validate those tests. However,CDC proposes to develope new guidelines to allow that when additional more specific test results are not immediately available, persons with repeatedly reactive HIV screening test results could be immediately counseled regarding the probability of their HIV infection. Clients/patients would also be informed of the need for confirmatory testing, medical follow-up and methods to reduce transmission. ~~~ to be continued ~~~~